Agenus Inc. Reports 20% Revenue Growth and Net Income Turnaround in Q3 2025

Agenus Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $30.2 million, a 20% increase from $25.1 million in the same period last year. The growth was primarily driven by a rise in non-cash royalty revenue related to the sale of future royalties, which increased to $29.1 million from $24.7 million, attributed to higher net sales of GlaxoSmithKline's vaccines containing the company's STIMULON QS-21 adjuvant. The company also recorded a net income of $63.9 million for the quarter, a significant turnaround from a net loss of $67.2 million in the prior year, largely due to a $100.9 million gain from the deconsolidation of MiNK Therapeutics, Inc.

In terms of operational changes, Agenus has seen a substantial reduction in its operating expenses, which fell to $34.1 million from $58.3 million year-over-year. This decrease was driven by a 43% reduction in research and development expenses, which totaled $23.6 million, and a 37% decline in general and administrative expenses, which amounted to $10.9 million. The company attributed these reductions to decreased headcount and lower third-party service costs, reflecting a strategic shift in its operational focus.

Agenus has also made significant strategic moves, including the deconsolidation of MiNK Therapeutics, which occurred when its ownership percentage fell below 50%. This change has led to the company accounting for its investment in MiNK under the equity method, with a fair value of approximately $30.5 million as of September 30, 2025. Additionally, Agenus entered into a $10 million Promissory Note Agreement with Zydus Pharmaceuticals, which is expected to bolster its liquidity as it navigates ongoing operational needs.

The company reported cash and cash equivalents of $3.5 million at the end of the third quarter, a decrease from $40.4 million at the end of 2024. However, Agenus anticipates additional cash inflows, including $91 million from agreements with Zydus Lifesciences Ltd, expected in the first quarter of 2026. Despite these projections, the company acknowledged substantial doubt about its ability to continue as a going concern over the next year, emphasizing the need for further funding to support its operations and product development initiatives.

Looking ahead, Agenus plans to continue its focus on immuno-oncology therapies, particularly its lead assets, botensilimab and balstilimab. The company is preparing for registration-enabling trials and is exploring various strategic options, including partnerships and licensing agreements, to advance its clinical programs. The management remains committed to addressing liquidity needs while navigating the complexities of the biotechnology landscape.